Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Condition(s) targeted: Secondary Hypogonadism

Intervention: Placebo (Drug); topical testosterone (Drug); Androxal (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Repros Therapeutics Inc.

Official(s) and/or principal investigator(s):
Larry Lipshultz, MD, Principal Investigator, Affiliation: Baylor College of Medicine

The Purpose of the study is to determine the effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism(confirmed morning Testosterone less than 250 ng/dL), compared to changes with placebo, or Testim (topical testosterone). The effects of Testim versus placebo on reproductive status will also be examined. Study subjects must not be currently using a topical testosterone.

Official title: A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Change in Total Morning Testosterone

Secondary outcome:

Change in Luteinizing Hormone Levels

Change in FSH After 3 Months of Treatment

Reproductive Safety

Detailed description: This study is a phase IIb, 4 arm study with three month active dosing period. Three of the four treatment groups will be randomized to either Androxal or placebo in a double-blind fashion, and the fourth treatment group will receive open-label Testim. The doses of Androxal in the blinded portion of the study will be 12. 5 mg and 25 mg, in capsule form.

Minimum age: 21 Years. Maximum age: 65 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Healthy males between the ages of 21 and 65 years of age

- All clinical laboratory tests within normal ranges (any clinically significant

deviation of laboratory results will require approval of sponsor)

- Previously or concurrently diagnosed as having secondary hypogonadism and confirmed

morning testosterone <250ng/dL (two assessments at least 10 days apart)

- Ability to complete the study in compliance with the protocol

- Ability to understand and provide written informed consent

- Agreement to use double barrier contraception if with a fertile female partner

- Agreement to provide a semen sample in the clinic

Exclusion Criteria:

- Use of an injectable, oral, topical, or subcutaneous pelleted testosterone within 6

months prior to study

- Use of spironolactone, cimetidine, Clomid, 5α-reductase inhibitors, hCG, androgen,

estrogen, anabolic steroid, DHEA, or herbal hormone products during the study

- Use of Clomid in the past year

- Uncontrolled hypertension or diabetes mellitus based on the Investigator's assessment

at baseline. Subjects treated for Type II diabetes but exhibiting glycemic control will be allowed into the study

- A hematocrit >50% or a hemoglobin >17 g/dL

- Clinically significant abnormal findings on screening examination

- Use of an investigational drug or product, or participation in a drug or medical

device research study within 30 days prior to receiving study medication

- Known hypersensitivity to Clomid

- Symptomatic cataracts (nuclear sclerosis cataract or cortical cataract grade > 2

based on 0-4 scale or any trace of posterior subcapsular cataract)

- Any condition which in the opinion of the investigator would interfere with the

participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study

- Irreversibly infertile or compromised fertility (cryptorchism, Kallman Syndrome,

primary hypogonadism, vasectomy, or tumors of the pituitary)

- Current or history of breast cancer

- Current or history of prostate cancer or a suspicion of prostate disease unless ruled

out by prostate biopsy, or a PSA>3. 6

- Presence or history of hyperprolactinemia with or without a tumor

- Chronic use of medications use such as glucocorticoids

- Subjects with cystic fibrosis (mutation of the CFTR gene)

- Subjects unable to provide a semen sample in the clinic

- Subject has a BMI >36 kg/m2

Paradigm Clinical Inc., Garden Grove, California 92844, United States

Northern California Research Corp, Sacramento, California 95831, United States

Medical Center for Clinical Research, San Diego, California 92108, United States

Los Angeles Biomedical Research Institute, Torrance, California 90502, United States

Affiliated Clinical Research, Las Vegas, Nevada 89109, United States

Affiliated Clinical Research Inc., Las Vegas, Nevada 89144, United States

Weill Cornell Medical College and Smith Institute, Great Neck, New York 11021, United States

Jed Kaminetsky, New york, New York 10016, United States

Natan Bar-Chama, New York, New York 10022, United States

Michael A Werner, Purchase, New York 10577, United States

Discovery Clinical Trials, Austin, Texas 78758, United States

Research Across America, Carrollton, Texas 75010, United States

Centex Research, Houston, Texas 77062, United States

Endocrine and Psychiatry Center, Houston, Texas 77095, United States

Texas Urology Specialist, Houston, Texas 77024, United States

Protenium Clinical Research, Hurst, Texas 76054, United States

R/D Clinical Research, Lake Jackson, Texas 77566, United States

Cetero Research, San Antonio, Texas 78229, United States

Sponsor website

Website

Starting date: January 2011
Last updated: June 27, 2014